Bayer
This article was originally published in The Tan Sheet
Executive Summary
Aleve pain reliever sales advanced 27.5% to $302.3 mil. (E1=$1.33) in 2006 (ended Dec. 31), Bayer announces March 15. One-A-Day achieved sales growth of 5.1% to $165.1 mil. and Alka-Seltzer revenues increased 6.3% to $101 mil. for the year, firm adds. The brands helped drive sales of Bayer's Consumer Health Consumer Care Division, which jumped 7.5% to $3.37 bil. for the year, the company reports, noting it doubled sales of its OTC pharmaceuticals franchise during the year. The Consumer Health segment had net sales of $5.66 bil., representing growth of 8.1%. The company is continuing expansion of the Consumer Health division abroad, particularly in China, with the recent purchase of OTC company Topsun's cough/cold portfolio (1"The Tan Sheet" Oct. 30, 2006, p. 9). The HealthCare group's net sales grew 46.6% to $15.62 bil., and earnings before interest, taxes, depreciation and amortization before special items soared 75.7% to $3.48 bil. Bayer is targeting underlying EBITDA margin growth of about 27% in HealthCare in 2009...
You may also be interested in...
Bayer Increases Chinese Presence With Topsun Cough/Cold Buy
Bayer expects its purchase of Topsun Science & Technology's nonprescription cough and cold portfolio to "substantially increase Bayer Consumer Care's presence in China, one of the fastest growing OTC markets in the world," the firm states Oct. 25
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.